Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

TAG-72 is a tumor-associated antigen identified by the monoclonal antibody B72.3. Serum levels of TAG-72 were measured in patients with non-malignant and malignant disease. TAG-72 is not a specific marker of cancer and slightly elevated levels of this antigen can also be detected in the serum of healthy subjects. However, our results show that specificity (92%) and positive predictive value (86%) of this marker are very high. TAG-72 levels above the cut-off limit of 6 U/mL were found in patients with tumors of various organs, including gastrointestinal, ovarian, lung and breast cancer. TAG-72 assay sensitivity is related to tumor stage with values being highest with advanced disease, especially in patients with gastric cancer and lung adenocarcinoma.
 ...
PMID:Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. 139 66

Krukenberg tumor, a malignant ovarian neoplasm with well defined histological characteristics, is often bilateral and secondary to a tumor of the gastrointestinal tract. We describe the case of a 44 year old woman affected by gastric cancer, who only 10 months after such diagnosis and subsequent total gastrectomy, came to our observation with ascites and bulky peritoneal involvement. During this period the patient achieved only haematochemical dosages of tumoral markers, particularly of TAG-72 which after 180 days rose to pathological values. We remark the importance of a careful clinical control and monitoring of TAG-72 for the follow-up of gastric cancer.
 ...
PMID:The Krukenberg tumor. A case report. 165 13

CA 72 is a monoclonal antibody (MAb) -defined antigenic determinant expressed on a pancarcinoma antigen (TAG-72) found in more than 85% of human colorectal carcinomas. An immunoradiometric assay has been developed using the murine MAb B72.3 to quantitate CA 72 in human serum. In a simultaneous immunoradiometric assay, the mean CA 72 concentration in 1,099 serum samples from healthy blood donors was 1.83 +/- 2.03 (SD) units/ml. If the upper limit of normal was set at 10 mu/mol of serum, a value including 99% of healthy blood donors, only 4 of 101 serum samples (4%) from patients with benign disease were elevated, whereas 15 of 26 (58%) and 14 of 25 (56%) of rectal and colon carcinoma patient sera, respectively, were positive. Serum samples from 84 benign colorectal disease cases were examined; of these, 0 of 28 (0%) colorectal adenoma, 1 of 39 (3%) ulcerative proctocolitis, 0 of 15 (0%) diverticulosis, and 0 of 2 (0%) irritable bowel disease sera contained more than 10 mu/ml CA 72. At a reference value of 20 mu/ml, 0 of 101 (0%) benign disease and 2 of 1,060 (0.2%) blood donor sera had elevated values, whereas 10 of 26 (38%) and 9 of 25 (36%) rectal and colon patient sera, respectively, remained positive. The majority of patients with pancreatic and ovarian cancer, and a significant fraction of stomach cancer patient sera, also contained elevated levels of CA 72. The ability of this assay to discriminate between malignant and benign diseases suggests its further evaluation for monitoring and diagnosis in groups at risk for development of cancer.
 ...
PMID:Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG-72). 242 34

Monoclonal antibody (MAb)B72.3 has been used to detect the presence of TAG-72 in the serum of carcinoma patients. We have developed new anti-TAG-72 MAbs and have selected one of these, CC49, as the "catcher" MAb with 125I-B72.3 as the detecting antibody in a double-determinant immunoradiometric assay. This combination enabled the development of a sequential assay (designated CA 72-4) that showed optimal quantitative properties as demonstrated by such parameters as linear dose-response, high re-producibility, and lack of serum-matrix and "hook-back" effects. Only 3.5% of 744 normal sera and 6.7% of 134 sera from patients with benign gastrointestinal diseases had TAG-72 levels greater than 6 U/ml. Approximately 40% of 303 patients with gastrointestinal malignancies had serum TAG-72 levels of greater than 6 U/ml (55% of the patients with advanced disease). Thirty-six percent of patients with adenocarcinomas of the lung and 24% of patients with ovarian cancer (53% stage IV patients) also had elevated serum TAG-72 levels. A poor correlation was found between the carcinoembryonic antigen (CEA) and TAG-72 values of sera obtained from gastric cancer patients. Thirty-four percent of CEA negative cases were scored positive in the CA 72-4 assay, suggesting the complementarity of the CA 72-4 assay to CEA assays in the analysis of sera from patients with certain malignancies.
 ...
PMID:CA 72-4 radioimmunoassay for the detection of the TAG-72 carcinoma-associated antigen in serum of patients. 261 71

Before surgical treatments, sera of 54 pts suffering from gastric cancer, histologically typed and clinically staged (from stage 0 to 4), were assayed to evaluate CEA, TPA, CA 19-9 and Ferritin versus a new tumoral marker called TAG-72, in order to determine the biological behaviour and the relation to the clinical stage of this last one. Starting from their results, Authors say that the new marker TAG 72 has an increasing sensibility according to the clinical stage (4 th more than 1 st), and that the association of the TAG-72 plus CEA and/or TPA is rather significant in order to evaluate the evolution of the gastric cancer than other markers.
 ...
PMID:[Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER]. 276 30

Tumor-associated glycoprotein (TAG-72) has been shown to be expressed in a wide variety of epithelial malignant tissues. We have investigated serum levels of TAG-72 antigen in patients with gastrointestinal cancer with a solid phase radioimmunometric assay (RIA), CA72-4, utilizing murine monoclonal antibodies CC49 and B72.3 which recognize the TAG-72 antigen. Elevated levels of serum TAG-72 antigen were found in 48% of 56 gastric carcinoma patients and 67% of 45 colorectal carcinoma patients. The serum concentrations of TAG-72 were compared to those of CA19-9 and CEA. The positive rates of CA19-9 in gastric carcinoma and colorectal carcinoma patients were 29% and 54%, and those of CEA were 52% and 60%, respectively. Elevated serum levels of TAG-72, CA19-9 and CEA were observed in 7%, 14% and 24%, respectively, of patients with benign disease, thus indicating a preferential expression of TAG-72, compared to CA19-9 and CEA, in gastrointestinal carcinoma patients versus in patients with benign disorder. A cocktail of CA72-4, CA19-9 and CEA RIAs increased positive rates to 68% in sera of gastric cancer patients and 84% in sera of colorectal cancer patients. Combination assays using CA72-4, CEA and CA19-9 RIAs for patients with benign gastrointestinal disorder, however, also increased the positive rate to 31%. These results indicate that CA72-4, CA19-9 and CEA RIAs may be complementary in detecting circulating tumor-associated antigens. It must be emphasized, however, that interpretation of the data provided by the combination serum assays requires careful consideration.
 ...
PMID:Comparison of serum assays for TAG-72, CA19-9 and CEA in gastrointestinal carcinoma patients. 281 Aug 23

CA72-4 is a novel quantitative immunoradiometric assay system utilizing two monoclonal antibodies CC-49 and B72.3, which recognize a tumor-associated glycoprotein (TAG-72). We have utilized the CA72-4 RIA kit to measure serum levels of TAG-72 in 205 patients with carcinoma and 192 patients without carcinoma. The cut-off value (4.0 U/ml) was obtained according to the levels and the distribution of CA72-4 in 468 healthy individuals. The positive rates in 82 patients with gastric cancer, 55 with colorectal cancer, 24 with pancreatico-choledochal cancer, 36 with breast cancer, and 3 with ovarian cancer were 52%, 55%, 46%, 39%, and 67%, respectively. Fifty percent of the sera from 205 patients with carcinoma demonstrated increased levels of CA72-4, whereas only 10% of the sera from 192 patients without evidence of malignancy showed levels more than 4.0 U/ml. The average level of serum CA72-4 in the patients with carcinoma was 38.6 U/ml, much higher than that (2.7 U/ml) in patients without malignancy. The patients with gastrointestinal cancer at advanced stages or at recurrence showed higher levels of serum CA72-4 than the patients with cancer at early stages. These results thus indicate that CA72-4 is clinically useful as a novel tumor marker, especially for monitoring serum levels of TAG-72 in patients with gastrointestinal cancer, breast cancer, ovarian cancer and other epithelial malignancies.
 ...
PMID:[Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4]. 316 66

We measured the concentration and distribution of tumor associated antigens, TAG-72 and CEA, in stomach cancer by in vitro quantitative autoradiography (IV-QAR). Frozen sections of 33 specimens were incubated with varying concentrations of 125I-labeled CEA-79.1 and B72.3 antibodies specific for carcinoembryonic antigen (CEA) and tumor-associated glycoprotein-72 (TAG-72), respectively. Computer analysis of specific antibody binding gave maximal binding values which were equal to the concentrations of the antigen or epitope. TAG-72 was detected in 25 specimens, at a concentration ranging from 8.4 to 562.9 pmol/g. CEA was detected in 32 of the 33 specimens and its concentration ranged from 8.8 to 525.3 pmol/g. The distribution of TAG-72 by IV-QAR coincided with that of the tumor cells in 41.4% of the pathologic lesions. The distribution of CEA coincided with the tumor cells in 80.5% of pathologic lesions, nearly twice the TAG-72. The concentration of TAG-72 was significantly higher in mucinous adenocarcinoma and mucin containing adenocarcinomas than other types of adenocarcinomas. There was no significant difference in the concentration of CEA among the pathologic types of stomach cancer. In summary, stomach cancer exhibited wide variations in TAG-72 and CEA expression. CEA expression was more frequent and homogeneous than TAG-72.
 ...
PMID:Concentration and distribution of tumor associated antigens TAG-72 and CEA in stomach cancer. 777 33

Serum levels of CEA, CA 19.9 and TAG-72 were measured in 79 patients with active gastric cancer, 47 with treated gastric cancer and no clinical evidence of the disease and 33 with benign gastric disease. In the patients with active gastric cancer TAG-72 was increased in 47%, CA 19.9 in 46% and CEA in 33%. The sensitivity of these markers was related to the stage of the disease, although upon comparison of stages I-II and III-IV significant difference was observed only for TAG-72. The combined use of two of the markers increased the sensitivity compared with the use of only one. The results suggest that the combination of TAG-72 and CA 19.9 may be useful in the post surgical management of patients with gastric cancer.
 ...
PMID:TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer. 799 41

The regulation by interferon-gamma (IFN-gamma) of the expression of seven distinct human tumor-associated antigens [M 110,000, carcinoembryonic antigen (CEA), nonspecific crossreacting antigen (NCA), CA19-9, 17-1A, TAG-72, and D612] was studied in eight human gastric cancer cell lines. Six of the seven tumor antigens have been well-characterized and reported to be expressed by human gastric carcinomas. The M(r) 110,000 antigen has been recently identified in six of the eight human gastric cancer cell lines and may represent a potentially novel gastric tumor antigen. IFN-gamma administration substantially increased the expression of the M(r) 110,000 antigen in six gastric tumor cell types, and, furthermore, induced its expression de novo in another gastric tumor cell line (GaCa). Constitutive CEA and NCA expression was detected on the surface of five of the eight gastric carcinoma cell lines. IFN-gamma treatment induced only a modest increase in the level of expression of those related antigens, but those changes were accompanied by increases in the level of the respective mRNA transcripts. Four other human tumor-associated antigens, TAG-72, CA19-9, D612, and 17-1A, were found either to be not constitutively expressed and/or not regulated by IFN-gamma. The results indicate the selective nature by which IFN-gamma regulates the M(r) 110,000 antigen and, to a lesser extent, the antigens of the CEA gene family.
 ...
PMID:Comparison of the interferon-gamma-mediated regulation of tumor-associated antigens expressed by human gastric carcinoma cells. 850 1


1 2 3 Next >>